Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.70 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.70 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.70 |
| ▸ | THPO | P40225 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 2/20 | 0.70 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.70 |
| ▸ | MEN1 | O00255 | 2/20 | 0.70 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.70 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.70 |
| ▸ | ACHE | P22303 | 1/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.70 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.70 |
| ▸ | DRD3 | P35462 | 1/20 | 0.70 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16085123 | 0.94 | HIF1A (0.78) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7797887 | 0.89 | HIF1A (0.89) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Sarcolysin SCHEMBL28338888 | 0.83 | HIF1A (0.94) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Melphalan SCHEMBL4697634 | 0.83 | HIF1A (0.94) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Sarcolysin SCHEMBL414671 | 0.82 | HIF1A (1.00) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| (R)-Melphalan SCHEMBL5873 | 0.82 | HIF1A (1.00) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Melphalan SCHEMBL563239 | 0.82 | HIF1A (1.00) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Melphalan SCHEMBL5325132 | 0.82 | HIF1A (1.00) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Melphalan SCHEMBL5872 | 0.82 | HIF1A (1.00) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| Sarcolysin SCHEMBL2680958 | 0.81 | HIF1A (0.97) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765720-B2 | Combination therapy for the treatment of multiple myeloma | CEPHALON, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120071445-A1 | Combination Therapy for the Treatment of Multiple Myeloma | CEPHALON, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071445-A1 | Combination Therapy for the Treatment of Multiple Myeloma | MCL1, BAK1, MCTS1 | CYP3A4 3546/4885ALDH1A1 1555/4885SMN1; SMN2 967/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.